The efficacy of anti-PD-1therapy depends on the presentation of neoantigens by major histocompatibility complex (MHC) class I molecules on the surface of cancer cells for surveillance by cytotoxic CD8+ T cells22. The gene discussed is CD8A; the disease is cancer.